Leverty Financial Group’s Theriva Biologics TOVX Stock Holding History

Leverty Financial Group’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1	Closed	–	–	114
2021 Q4	$0	Buy	+1	New	+$94	﹤0.01%	131

Other funds holding TOVX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Leverty Financial Group's TOVX Position: Q1 2022 in Review

Leverty Financial Group sold out of Theriva Biologics (TOVX) in Q1 2022, closing a stake of 1 share.

Leverty Financial Group first reported a position in TOVX in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 32 funds tracked by Wall St. Rank hold TOVX as of Q1 2022.

Leverty Financial Group reported no remaining Theriva Biologics position as of Q1 2022 after selling out during the quarter.
Leverty Financial Group sold 1 Theriva Biologics share in Q1 2022.
Leverty Financial Group first reported a position in Theriva Biologics in Q4 2021 and held it in 1 quarter.
Leverty Financial Group's Theriva Biologics position peaked at $0 in Q4 2021.
32 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2022.

Based on Leverty Financial Group's 13F filing for Q1 2022, filed 20 Apr 2022.